Episode 8

**BEYOND THE SCAN PODCAST SCRIPT**

---

**INTRO**

Hey there, welcome to "Beyond the Scan"! I'm Jackie, your host, and I'm so glad you're joining me today, Wednesday, June 25, 2025.

Quick shoutout to our sponsor RadiologyJobs.com—they're doing amazing work connecting imaging professionals with great opportunities nationwide.

I've got some really exciting stories to share with you today!

---

**MAIN CONTENT**

You know what? I have to start with this first story because... <break time="1.0s" /> well, it honestly gave me chills when I first read it. We're talking about a true game-changer here, folks.

The FDA just granted the very first autonomous AI clearance for something called "LungGuard AI" from a startup called Caelus Diagnostics. Now, let me break this down for you because this is absolutely revolutionary. This isn't just another AI tool that helps radiologists – this is an AI that can actually work on its own to detect and classify lung nodules on chest CT scans.

Think about it this way... when you get a chest CT for any reason – maybe you're in the ER after an accident, or you're getting screened for something completely unrelated – sometimes the scan picks up these little spots on your lungs called nodules. Most of the time, they're benign, but they need to be tracked and monitored. Well, now we have an AI that can spot these nodules, measure them, and even make recommendations following established medical guidelines – all without a radiologist having to review it first.

The numbers here are just... they're incredible. In testing with over 15,000 scans, this AI showed 97% sensitivity and 94% specificity. That means it's catching 97 out of 100 nodules that are actually there, and it's correctly identifying 94 out of 100 cases that don't have significant nodules. And get this – it actually outperformed human radiologists when it came to detecting those really tiny nodules under 5 millimeters.

Now, I know what some of you might be thinking... <break time="0.8s" /> are we replacing radiologists? And honestly, that's the big question everyone's asking. The radiologist still has to sign off on the final report, but this autonomous workflow is – it's a huge leap forward. Some people are saying this will free up radiologists to focus on the really complex cases, while others are worried about becoming too dependent on machines.

But here's what I think is really exciting about this – we're talking about standardizing care for something that's actually pretty common. No more missed nodules because someone was having an off day, or because the nodule was in a tricky spot. That's... that's pretty amazing for patient care.

---

Alright, now I've got to shift gears here and talk about something that's not quite as exciting, but it's definitely something every radiologist needs to know about. <break time="1.2s" /> CMS – that's the Centers for Medicare & Medicaid Services – just proposed some cuts that are making waves across our entire field.

They're proposing a 4.5% cut to reimbursement for advanced imaging in 2026. We're talking MRI, CT, PET scans – the works. And their reasoning? They say they need to balance the budget to increase funding for primary care visits.

Now, I get it – primary care is important, absolutely. But Dr. Eleanor Vance from the American College of Radiology put it perfectly when she called this "devastating and short-sighted." Because here's the thing... these cuts don't happen in a vacuum.

When reimbursement gets cut, especially by this much, some imaging centers are going to struggle. Some might even have to close, particularly in rural areas where margins are already tight. And when that happens, patients suffer. They have to travel further for their scans, wait longer for appointments... it's a ripple effect that goes way beyond just the financial impact on practices.

I really encourage everyone listening – whether you're a radiologist, a tech, or just someone who cares about healthcare access – to get involved during this 60-day comment period. The ACR is mobilizing, but they need our voices. Because at the end of the day, these imaging studies... they save lives. They catch cancers early, they guide treatments, they prevent unnecessary surgeries. That's worth fighting for.

---

Okay, let me brighten things up a bit with this next story because... <break time="0.7s" /> oh my goodness, this is the kind of breakthrough that reminds me why I love covering medical advances.

We've got results from something called the SYN-DETECT Phase III trial, and folks, this could change everything for Parkinson's disease diagnosis. They've developed a new PET tracer – it's called F-SYN1 – that can actually see the protein clumps in the brain that cause Parkinson's disease.

Now, here's why this is so huge. Until now, the only way to definitively confirm that someone had the protein deposits that cause Parkinson's was... well, after they died, during an autopsy. Can you imagine? Doctors have been diagnosing Parkinson's based on symptoms and clinical judgment, but they couldn't actually see what was happening in the brain of a living person.

This new tracer showed 95% sensitivity and 92% specificity in a study of 450 patients. That means we can now look at someone's brain scan and say with confidence, "Yes, you have the biological markers of Parkinson's disease," or "No, your symptoms might be caused by something else entirely."

And here's what gets me really excited... this isn't just about diagnosis. Think about clinical trials for new Parkinson's treatments. Right now, researchers sometimes include patients who don't actually have the disease – they just have similar symptoms. But with this tracer, they can make sure they're testing treatments on people who definitely have the disease. That's going to make drug development so much more efficient.

For nuclear medicine physicians and radiologists, this represents a completely new diagnostic capability. We're moving from educated guessing to biomarker-confirmed certainty. It's... it's pretty incredible, really.

---

And finally, I want to wrap up with some fantastic news for my interventional radiology colleagues out there. The ACCESS trial just gave us some really clear guidance on the best way to treat small kidney cancers using minimally invasive techniques.

So here's the setup – when someone has a small kidney tumor, under 4 centimeters, there are a couple of ways to treat it without major surgery. You can use radiofrequency ablation – that's RFA, where you essentially heat up and destroy the tumor – or you can use cryoablation, where you freeze it to death instead.

This trial directly compared these two approaches over five years, and the results were pretty definitive. Cryoablation had a 98.1% success rate at two years, compared to 91.5% for RFA. And patients who got RFA were three times more likely to need a repeat procedure.

Dr. Marcus Thorne, who led the study, explained that when you're doing cryoablation, you can actually see the ice ball forming around the tumor on the CT or ultrasound. It's like... you have this visual confirmation that you're getting complete coverage of the tumor. With heat-based treatments, it's a bit more of a guessing game.

For patients, this is great news because it means we now have clear evidence about which treatment is most likely to work the first time. And for interventional radiologists, this kind of head-to-head data is gold. It's going to influence treatment guidelines and probably change how IR departments think about their equipment investments.

You know, this is exactly the kind of evidence-based medicine that makes our field stronger. No more wondering "which approach is better?" – now we know.

---

**OUTRO**

Well, that's all we have for today's episode of "Beyond the Scan." I've really enjoyed sharing these developments with you.

If you found today's discussion helpful, I'd love it if you'd subscribe and share with your colleagues. And hey, swing by our website at beyondthescan.com where we've got some great additional resources on these topics.

I'll be back next week with more exciting updates. This is Jackie signing off, and remember—what we do really does make a difference in people's lives every day. Take care!